Cytokinetics

A late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These treatments are aimed at addressing debilitating diseases where cardiac muscle performance is compromised, setting the company apart with its innovative approach to muscle biology. The primary beneficiaries of Cytokinetics' work are patients suffering from severe cardiovascular and neuromuscular diseases.

Cytokinetics was discovered on February 1st 2023 and it currently has a search volume of 18.1K with a growth of +533%.